Sub is a weird drug: A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms

American Journal on Addictions

Volumn 24, Issue 5, 2015, Pages 403-409

  Daniulaityte, Raminta ^a   Carlson, Robert ^a   Brigham, Gregory ^b   Cameron, Delroy ^c   Sheth, Amit ^c  

^a WRIGHT STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; HYDROCODONE; OPIATE; OXYCODONE; BUPRENORPHINE PLUS NALOXONE;

ARTICLE; ATTITUDE; DRUG EFFICACY; DRUG USE; HEALTH HAZARD; SELF MEDICATION; WITHDRAWAL SYNDROME; ADULT; ATTITUDE TO HEALTH; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; MIDDLE AGED; OPIOID-RELATED DISORDERS; PSYCHOLOGY; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME; TRENDS;

ADULT; ATTITUDE TO HEALTH; BUPRENORPHINE, NALOXONE DRUG COMBINATION; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; HYDROCODONE; INTERNET; MIDDLE AGED; OPIOID-RELATED DISORDERS; OXYCODONE; SELF MEDICATION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84937972612     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12213     Document Type: Article

References (35)

1. Center for Substance Abuse Treatment,. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
2. Johnson RE, Strain EC, Amass L,. Buprenorphine: How to use it right. Drug Alcohol Depend. 2003; 70:(2 Suppl): S59-S77.
3. Mattick RP, Breen C, Kimber J, et al., Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014; 2: D002207.
4. Office of Diversion Control,. National Forensic Laboratory Information System (NFLIS) Special Report: Methadone and Buprenorphine, 2003-2008. Washington, DC: U.S. Drug Enforcement Administration; 2009.
5. Dasgupta N, Bailey EJ, Cicero T, et al., Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010; 11: 1078-1091.
6. Wish ED, Artigiani E, Billing A, et al., The emerging buprenorphine epidemic in the United States. J Addict Dis. 2012; 31: 3-7.
7. Substance Abuse and Mental Health Services Administration (SAMHSA),. The DAWN Report: Emergency Department Visits Involving Buprenorphine. Rockville, MD: SAMHSA; 2013.
8. Yokell MA, Zaller ND, Green TC, et al., Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011; 4: 28-41.
9. Schuman-Olivier Z, Albanese M, Nelson SE, et al., Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010; 39: 41-50.
10. Monte AA, Mandell T, Wilford BB, et al., Diversion of buprenorphine/naloxone co-formulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009; 28: 226-231.
11. Bazazi AR, Yokell M, Fu JJ, et al., Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011; 5: 175-180.
12. Daniulaityte R, Falck R, Carlson RG,. Illicit use of buprenorphine in a community sample of young adult non-medical users of pharmaceutical opioids. Drug Alcohol Depend. 2012; 122: 201-207.
13. Genberg BL, Gillespie M, Schuster CR, et al., Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addict Behav. 2013; 38: 2868-2873.
14. Lofwall MR, Havens JR,. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012; 126: 379-383.
15. Schifano F, Deluca P, Baldacchino A, et al., Drugs on the web: The Psychonaut 2002EU project. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30: 640-646.
16. Miller PG, Sonderlund AL,. Using the internet to research hidden populations of illicit drug users: A review. Addiction. 2010; 105: 1557-1567.
17. Kleinman A, Eisenberg L, Good B,. Culture, Illness, and care: Clinical lessons from anthropologic and cross-cultural research. Ann Intern Med. 1978; 88: 251-258.
18. Butler SF, Venuti SW, Benoit C, et al., Internet surveillance: Content analysis and monitoring of product-specific internet prescription opioid abuse-related postings. Clin J Pain. 2007; 23: 619-628.
19. Davey Z, Schifano F, Corazza O, et al., Psychonaut Web Mapping Group. e-Psychonauts: Conducting research in online drug forum communities. J Ment Health. 2012; 21: 386-394.
20. Daniulaityte R, Carlson R, Falck R, et al., "I just wanted to tell you that loperamide WILL WORK": A Web-based study of extra-medical use of loperamide. Drug Alcohol Depend. 2013; 130: 241-244.
21. Boyer EW, Babu KM, Macalino GE,. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007; 16: 352-356.
22. Cameron D, Smith GA, Daniulaityte R, et al., PREDOSE: A semantic web platform for drug abuse epidemiology using social media. J Biomed Inform. 2013; 46: 985-997.
23. Eysenbach G., Infodemiology and infoveillance: Framework for an emerging set of public health informatics methods to analyze search, communication and publication behavior on the Internet. J Med Internet Res. 2009; 11: e11.
24. Benton A, Ungar L, Hill S, et al., Identifying potential adverse effects using the Web: A new approach to medical hypothesis generation. J Biomed Inform. 2011; 44: 989-996.
25. Sudweeks F, Simoff SJ,. Complementary explorative data analysis: The reconciliation of qualitative and quantitative principles. In:, Jones S, ed. Critical Issues and Methods for Examining the Net, pp. 29-56. Thousand Oaks, CA: Sage Publications; 1999.
26. Neuendorf KA,. Reliability for content analysis. In:, Jordan AB, Kunkel D, Manganello J, Fishbein M, eds. Media Messages and Public Health: A Decisions Approach to Content Analysis, pp. 67-87. New York: Routledge; 2009.
27. Cicero TJ, Ellis MS, Surratt HL,. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012; 367: 187-189.
28. Ling W, Amass L, Shoptaw S,. et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005; 100: 1090-1100.
29. Hser YI, Saxon AJ, Huang D,. et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014; 109: 79-87.
30. Thomas V, Heath M, Rose D, et al., Psychological characteristics and the effectiveness of patient-controlled analgesia. Br J Anaesth. 1995; 74: 271-276.
31. Chiauzzi E, Dasmahapatra P, Lobo K, et al., Participatory research with an online drug forum: A survey of user characteristics, information sharing, and harm reduction views. Subst Use Misuse. 2013; 48: 661-670.
32. Bruckman A,. Studying the amateur artist: A perspective on disguising data collected in human subjects research on the internet. Ethics Inf Technol. 2002; 4: 217-231.
33. Mounteney J, Fry C, McKeganey N, et al., Challenges of reliability and validity in the identification and monitoring of emerging drug trends. Subst Use Misuse. 2010; 45: 266-287.
34. Agar MH,. Folks and professionals: Different models for the interpretation of drug use. Int J Addict. 1985; 20: 173-182.
35. McHugh M,. Interrater reliability: The kappa statistic. Biochemia Medica. 2012; 22: 276-282.